Brief: Beyondspring Announces Late-Breaking Oral Presentation Of Final Phase 3 Data With The Plinabulin/Docetaxel Combination In Non-Small Cell Lung Cancer
31/08/2021 12:32
Aug 31 (Reuters) - Beyondspring Inc BYSI.O :
* BEYONDSPRING ANNOUNCES LATE-BREAKING ORAL PRESENTATION OF
FINAL
PHASE 3 DUBLIN-3 DATA WITH THE PLINABULIN/DOCETAXEL COMBINATION
VERSUS DOCETAXEL ALONE IN 2ND/3RD LINE NON-SMALL CELL LUNG
CANCER PATIENTS WITH EGFR WILD TYPE AT THE EUROPEAN SOCIETY FOR
MEDICAL ONCOLOGY 2021 CONGRESS
Source text for Eikon: ID:nGNXbGt7zP
Further company coverage: BYSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value